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Background: Gene mutations that produce misprocessed proteins are linked to many human disorders.
Interestingly, some misprocessed proteins retained their biological function when stabilized by low temperature
treatment of cultured cells in vitro. Here we investigate whether low temperature treatment in vivo can rescue
misfolded proteins by applying 5’-AMP mediated whole body cooling to a Cystic Fibrosis (CF) mouse model
carrying a mutant cystic fibrosis transmembrane conductance regulator (CFTR) with a deletion of the phenylalanine
residue in position 508 (ΔF508-CFTR). Low temperature treatment of cultured cells was previously shown to be able
to alleviate the processing defect of ΔF508-CFTR, enhancing its plasma membrane localization and its function in
mediating chloride ion transport.
Results: Here, we report that whole body cooling enhanced the retention of ΔF508-CFTR in intestinal epithelial
cells. Functional analysis based on β-adrenergic dependent salivary secretion and post-natal mortality rate revealed
a moderate but significant improvement in treated compared with untreated CF mice.
Conclusions: Our findings demonstrate that temperature sensitive processing of mutant proteins can be
responsive to low temperature treatment in vivo.
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Increasing evidence has indicated that incorrect folding
of proteins is the underlying cause of many human dis-
orders and diseases, including Cystic Fibrosis (CF),
Amyotrophic lateral sclerosis (ALS), Parkinson’s disease
(PD) and Alzheimer’s disease (AD) [1, 2]. In a healthy
cellular environment, misfolded proteins fail to pass the
“quality control” of the endoplasmic reticulum (ER) and
are retained and selectively degraded without being
exported. These are typically described as trafficking de-
fects since the misfolded proteins fail to reach their tar-
get sites. Thus, these disorders result from the loss of
functional protein, as in CF [3–5]. In other cases, such* Correspondence: Cheng.C.Lee@uth.tmc.edu
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folded proteins evade the “quality control” of the ER,
and form aggregates that disrupt normal cellular pro-
cesses [6].
In efforts to identify ways to correct protein misfold-
ing, researchers have found that many of the misfolding
defects are temperature-sensitive and can be corrected,
or partially corrected, by low temperature treatment of
cultured cells. For example, congenital long QT syn-
drome is caused by mutations in the human ether-a-go-
go-related gene (HERG) encoding a potassium channel.
When cells were incubated at low temperature (27 °C),
the expression of two trafficking-deficient mutations of
long QT, HERG N470D and HERG R752W, resulted in
improved incorporation of functional channels into the
plasma membrane [7]. The receptor tyrosine kinaseis distributed under the terms of the Creative Commons Attribution 4.0
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ney and the enteric nervous system. Missense mutations
prevent its expression at the cell surface and lead to
Hirschsprung disease, but low temperature (30 °C) could
largely rescue the trafficking defect of the mutant pro-
tein [8]. Similarly, the common H1069Q mutation re-
sponsible for Wilson’s disease is due to a defect in the
trafficking of this copper-dependent protein which can
be rescued by lowering the temperature to 28 °C [9].
Two mutations in the pancreatic ATP-sensitive potas-
sium channels A116P and V187D, located in the SUR1
subunit, reduce channel activity leading to persistent in-
fancy hyperinsulinemic hypoglycemia. The temperature
sensitive misfolding of each mutated protein observed at
37 °C was completely rescued at 18 °C [10]. Tyrosinase
is an enzyme present in melanocytes involved in the syn-
thesis of melanin. Mutations in this enzyme that retain
the protein in the endoplasmic reticulum can cause ocu-
locutaneous albinism. The Golgi processing and trans-
port of the tyrosinase mutants to melanosomes was
promoted by reducing the incubation temperature from
37 to 32 °C [11].
The low temperature rescue of mutant proteins causing
CF has been intensively studied. CF is caused by muta-
tions in the gene encoding the cystic fibrosis transmem-
brane conductance regulator (CFTR). The CFTR is an
anion channel critical for fluid and electrolyte homeostasis
at the epithelial surfaces of many organs, including lung,
salivary glands and intestine. The loss of functional
CFTR channels at the plasma membrane disrupts ionic
(Cl−, Na+, HCO3−) homeostasis, which leads to thick-
ened mucus, obstructed secretion ducts and reduced
hydration of organs. The most common mutation is a
triple nucleotide deletion in the CFTR gene, resulting
in deletion of a phenylalanine at amino acid position
508 of the CFTR protein (ΔF508). This mutation ac-
counts for approximately 70 % of defective CFTR alleles
[12] and 90 % of CF patients in the United States carry
at least one such allele [13]. Studies have shown that
the mRNA for ΔF508-CFTR is transcribed and trans-
lated, but the mutant protein remains trapped in the
ER, where it is recognized as a misfolded protein and
rapidly degraded by the ubiquitin proteasome pathway
before it can reach the plasma membrane [14]. Early
studies showed that some post-translational processing
of ΔF508-CFTR is temperature sensitive [15, 16]. When
expressed in cells at 37 °C, ΔF508-CFTR is present pre-
dominantly as a 130 kDa unglycosylated form (band A).
When cells are grown at a lower temperature (26 °C),
the percentages of the 150 kDa core-glycosylated form
(band B) and the mature fully glycosylated form
(170 kDa, band C) were each increased. The percentage
of ΔF508-CFTR in complex glycosylation forms pro-
gressively increased as incubation time at the reducedtemperature (26 °C) progressed. The rescued ΔF508
was delivered to the plasma membrane and exhibited
significant Cl− transport activity [16, 17]. Decreasing
the temperature to 16 °C was shown to be more effect-
ive in stabilizing ΔF508-CFTR in cultured cells [18]. A
recent study further showed that low temperature treat-
ment facilitated the restoration of ΔF508-CFTR activity
in dissected intestinal tissue maintained in vitro [19].
These studies raise the possibility that a reduction in
whole body temperature may attenuate the processing
defect of mutant CFTR and restore all or some function
in vivo. However, it remains unclear whether ΔF508-
CFTR, after cooling in vivo, would behave in a similar
manner to that shown in vitro, as reducing whole body
temperature for such a study has not been reported.
Previously, we have shown that 5’-AMP induces re-
versible hypometabolism in large and small mammals
[20, 21]. 5’-AMP induced hypometabolism (AIHM) was
used to reduce core body temperature (Tb) of mice to
about 16 °C for several hours at an ambient temperature
(Ta) of 15 °C while allowing the animal to safely recover
to the euthermic state [22, 23].
The aim of the present study is to investigate whether
a whole body cooling strategy can rescue the temperature-
sensitive misfolding and processing defect of a mutant
protein in vivo. We have chosen to investigate the efficacy
of AIHM in rescuing ΔF508-CFTR and restoring its func-
tion in CF mice, in vivo.
Methods
Mice
CftrF508 del mice (B6.129S6-Cftrtm1Kth/J), a mouse model
for CF caused by the ΔF508 mutation, are used in this
study [24]. Heterozygote parent CF mice and wild type
mice were purchased from the Jackson Laboratory. All
mice used in this investigation were provided with regu-
lar chow and water ad libitum. All animals are moni-
tored at least once every 24 h by laboratory personnel or
animal care staff. Mice were housed in standard hus-
bandry conditions under a 12-h/12-h light/dark cycle at
an ambient temperature (Ta) of 23 °C. Although both
homozygote CF males and females are fertile, the fe-
males appeared to have poor capability to rear their
young. Thus, each cage started with one homozygote
male mating with two heterozygous females, and the
males were removed after 2 weeks. Each pregnant female
typically delivered 6–8 pups. Cages were examined daily
to monitor the approximate time of birth and to assess
mortality. Tissue samples from deceased animals were
collected for genotyping and tail clips from live animals
were collected at weaning for genotyping using a PCR
method provided by the Jackson Laboratory. The studies
were carried out under animal protocols HSC-AWC-09-
010 approved by the Animal Welfare Committee
Zhang et al. Journal of Biomedical Science  (2015) 22:72 Page 3 of 12(AWC), which is the institutional animal care and use
committee (IACUC) at the University of Texas Health
Science Center - Houston. All care and use of animals
for this study was in full compliance with animal welfare
guidelines of the AWC.Induction of deep hypometabolism in CF mice
Adenosine 5’-monophosphate was obtained from Sigma
(St Louis, MO, USA). A freshly prepared 5’-AMP solu-
tion in phosphate buffered saline was administered to
mice by intraperitoneal injection (ip) at a dosage of
0.5 mg/g body weight. After 5’-AMP injection, mice
were maintained at a Ta of 15 °C, in separate beakers to
facilitate cooling. Once mice entered deep stupor with a
Tb of 16–17 °C, they were transferred to microisolator
cages with bedding kept at a Ta of 15 °C. After keeping
mice in the stupor state for up to 10 h, Ta was increased
in a gradient manner from 15 °C to 17 °C to enhance
arousal and re-warming. For CF mice undergoing a lon-
ger period of stupor, the Ta was kept at 14.5 °C using a
refrigerated Comprehensive Lab Animal Monitoring
System (CLAMS, Columbus Instruments) and 200 μl of
saline was administrated at 7 h after administration of
5’-AMP. Mice that remained in stupor after 17 h were
gradually rewarmed to induce arousal. All re-warming
took place in a cage with food and water ad libitum.
Oxygen consumption and carbon dioxide production
rates were also monitored. Mouse body temperature
(Tb) was manually monitored by a digital thermometer
(Traceable, Fisher; catalogue no. 15-077-8) placed into
the rectum [21].Immunofluorescence staining
Briefly, the duodenum, defined as the first 3 cm of the
small intestine, was dissected from wild type, untreated
CF and CF mice treated by whole body cooling. The
duodenum was fixed with 4 % paraformaldehyde solu-
tion and then embedded in paraffin before being sec-
tioned. Paraffin-embedded mouse small intestine was
sectioned in 5 μm thick slices. For anti-CFTR staining,
sections were pretreated by heat-induced epitope re-
trieval, blocked in 10 % goat serum for 1 h and then in-
cubated overnight with primary antibodies for CFTR
(NB100-92156, Novus Biologicals) at 1:100 in incubation
medium (PBS with 3 % goat serum, 3 % BSA, and 0.3 %
Triton × 100). After four 5 min washes in washing buffer,
the sections were incubated with secondary antibodies
(Alexa Fluor 555–labeled goat anti-rabbit IgG; Invitro-
gen) for 1 h at room temperature at a concentration of
2 μg/ml in incubation medium. After four washes for
five min each, cover slips were mounted with SlowFade
Gold antifade reagent with DAPI (Invitrogen). Some
slides were co-stained with wheat germ agglutinin, AlexaFluor® 488 conjugate (Invitrogen), to visualize mucin se-
creted by goblet cells in mouse intestine.Mucin staining
WT or CF mouse small intestines were fixed overnight
in cold Carnoy’s solution (ethanol-acetic acid-chloroform
at a ratio of 6:3:1 by volume). The fixed tissues were proc-
essed in paraffin and cross sections (5 μm thick) were pre-
pared. The sections were stained for mucin using periodic
acid-Schiff (PAS)-Alcian blue (AB; pH 2.5) [25, 26].Isolation of mouse intestinal epithelium
The duodenal epithelium from the crypt and villus re-
gions was isolated by a modification of the Flint et al.
(1991) method [27]. Briefly, the small intestine duode-
num was removed, inverted, mounted on a 4 mm diam-
eter glass rod and divided into 2–3 mm lengths. The
inverted segments were flushed by constant stirring in
100 ml of cold Hanks’ solution containing 0.5 mM
dithiothretol at 4 °C for five min, transferred to 150 ml
of cold chelating buffer (0.5 mM dithiothretol, plus pro-
tease inhibitor cocktail) and incubated at 4 °C with con-
stant stirring for 20 min. The chelating buffer (pH 7.3)
included 27 mM trisodium citrate, 5 mM Na2HPO4,
96 mM NaCl, 8 mM KH2PO4, 1.5 mM KCl, 0.5 mM di-
thiothreitol, 55 mM D-sorbitol and 44 mM sucrose. The
detached epithelium was collected by centrifugation at
3,000 x g at 4 °C for 8 min and the pellets were sus-
pended in 5 ml lysis buffer containing 50 mM Tris–HCl
(pH 7.4), 0.25 mM sodium deoxycholate, 150 mM so-
dium chloride, 2 mM EDTA, 0.1 mM sodium orthovana-
date, 10 mM sodium fluoride, 1 mM PMSF, 1 % triton
X-100, plus protease inhibitor cocktail (Roche), mixed
vigorously on a vortex mixer, then kept on ice for 30 min
and centrifuged at 14,000 rpm at 4 °C for 10 min. The
supernatant was collected and stored at −80 °C [27].Western blot analysis
The protocol was largely as previously described [28].
Briefly, the detached epithelial cell lysates were mixed
with 2X modified Laemmli Sample Buffer containing
8 M urea and incubated for 30 min at room temperature.
Following centrifugation (2 min, 8,000 x g), samples of the
supernatant (adjusted to 40–50 μg protein) were separated
on a 6 % polyacrylamide gel. Immunoblot analysis was
performed with an anti-CFTR antibody (NB100-92156,
Novus Biologicals), followed by incubation with a second-
ary antibody conjugated with horseradish peroxidase. Per-
oxidase activity was detected by incubating with Luminata
Forte Western HRP substrate (Millipore) and exposure to
X-ray film (Kodak® BioMax® XAR Film).
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The methods used were similar to those described by
Best and Quinton [29]. In brief, mice were anaesthetized
with isoflurane and maintained on a flat surface in a su-
pine orientation with adhesive tape. The mouth was held
open by cephalic retraction of the dorsal front teeth with
a rubber band. An indirect heat lamp warmed the ani-
mals during the saliva collection period. Mice were pre-
treated with a subcutaneous injection of 50 μl (1 mM)
atropine into the left cheek as a cholinergic antagonist.
A pre-weighed 2 × 25 mm piece of Whatman filter paper
was placed inside the injected cheek for approximately
4 min to absorb any saliva. A solution (100 μl) contain-
ing 100 μM isoprenaline and 1 mM atropine was then
injected into the left cheek at the same site to induce se-
cretion at time zero and the filter paper was replaced
every three minutes for next thirty minutes. Each piece
of filter paper was immediately sealed in a pre-weighed
vial and the time of removal was recorded. The differen-
tial in weight of the vial pre and post secretion deter-
mined the amount of saliva secreted. The total salivary
secretion was normalized to the mass of the mouse in
grams. Results are expressed as μg min−1 g−1 (mean ±
SEM).
Results
5’-AMP-induced whole body cooling increases ΔF508-CFTR
levels in CF mouse intestine
To investigate the effect of whole body cooling at the tis-
sue and cellular levels, we examined CFTR expression in
intestinal duodenum epithelia. Previous studies showed
that CFTR is expressed mainly in the goblet cells in epi-
thelia of intestinal duodenum in the mouse and human
[30, 31]. We initiated whole body cooling of mice at a Ta
of 15 °C by intraperitoneal (IP) injection of 5’-AMP. The
Tb of the mice dropped to 16–17 °C within 1 h and
remained at this temperature for 7–10 h before they
spontaneously aroused from this deep hypometabolic
state [20]. Initially, we carried out immnunostaining of
intestinal epithelia from wild type and untreated CF
mice. Immunostaining of CFTR was strong in the goblet
cells of duodenal epithelia from wild type and was
largely absent in CF mice (Fig. 1a). To assess the stability
of ΔF508-CFTR protein after whole body cooling, we ex-
amined duodenal tissues from CF mice collected at 24 h,
48 h and six days post-treatment, using corresponding
tissues from wild type mice as controls (Fig. 1a). We
quantified the number of CFTR-positive goblet cells in
selected visual fields. About 60 % of the goblet cells were
positive for CFTR in treated CF mouse duodenum at
24 h post cooling. However, fewer CFTR positive cells
that were expressing high levels of CFTR were apparent
at 48 h post cooling. Six days after the treatment, the
percentage of the CFTR positive cells in duodena fromtreated animals was indistinguishable from that of un-
treated CF mice. These findings suggest that the increase
in ΔF508-CFTR stability after whole body cooling is tem-
porary. Next, we investigated whether ΔF508-CFTR stabil-
ity could be enhanced if CF mice were treated with a
regime of sequential cooling. For this group, the same
whole body cooling treatment was repeated 72 h after the
initial cooling (Fig. 1b). At 24 h after the second treat-
ment, immunostaining revealed that the total percentage
of CFTR-positive goblet cells in CF duodenal epithelia was
similar to that observed after a single cooling treatment
and it declined at 48 h and six days post-treatment. How-
ever, the number of CFTR-positive goblet cells in CF
mouse intestine at day six post-treatment remained sig-
nificantly higher than that of untreated CF mice suggest-
ing that repeated whole body cooling treatments have
added benefit in stabilizing ΔF508-CFTR proteins.
Increased ΔF508 CFTR stability and glycosylation
following whole body cooling treatments
The apparent increased retention of F508-CFTR in the
intestine of CF mice after whole body cooling observed
by immunofluorescence staining analysis was further
verified by Western analysis. Western analysis of de-
tached intestinal duodenal epithelial cells would also re-
veal the glycosylation status of ΔF508-CFTR following
whole body cooling treatment. Three gross glycosylation
stages of CFTR have been associated with three bands
observed by Western analysis: band A, the newly synthe-
sized unglycosylated form is about 130 kDa; band B, the
core-glycosylated form is about 150 kDa, and band C,
the complex glycosylated form is about 170 kDa [32]. As
expected, intestinal epithelial cells from individual CF mice
expressed either undetectable or low levels of ΔF508-
CFTR, primarily as band A. Bands B and C were generally
absent in the intestinal duodenal epithelium of CF mice
(Fig. 2a). In contrast, the majority of CFTR from wild type
intestinal duodenal epithelia were higher molecular weight
proteins migrating around 170 kDa reflecting the dif-
ferent glycosylated stages of the proteins correspond-
ing to bands B to C, with a significant portion
remaining in band A. The protein band pattern of wild
type compared to CF intestinal epithelial cells indi-
cated that the anti-CFTR antibodies have recognized
CFTR specifically. It was noticed that a component of
the polyclonal antibodies reacted with a protein band
at 72 kDa, which is present in both wild type and CF
epithelia. This non-specific band was used as an in-
ternal control for protein loading on the gel. Western
analysis of similar tissues from CF mice that have
undergone multiple cycles of whole body cooling treat-
ments showed a marked increase in total ΔF508-CFTR
retention relative to the internal control band (Fig. 2a).
Compared to untreated CF mice, the level of band A
Fig. 1 5’-AMP induced whole body cooling increases ΔF508-CFTR expression levels in CF mouse intestine. Representative cross-sections of mouse
duodenal crypts from WT, untreated CF and treated CF mice were immunostained with anti-CFTR rabbit polyclonal antibody (red) and counter stained
with DAPI (blue): a Treated CF mice that have undergone one treatment of 5’-AMP whole body cooling. b Treated CF mice that have undergone two
treatment cycles. CF mice were sacrificed post-treatment at 24 h, 48 h and six days for tissue analysis. Quantification of ΔF508-CFTR expression was
based on either positive or negative signals in intestinal goblet cells in equivalent visual fields in the respective genotype and treatment group
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treated CF mice was strikingly enhanced. Upon longer
exposure of the Western blot, a small amount of band
C was apparent and was not detected in any of the
samples from untreated CF mice. This observation
raised the possibility that the cellular processing of
ΔF508-CFTR was terminated prematurely possibly due
to an insufficient cooling period required for the full
glycosylation process.
Next, we investigated whether the level of band C
was increased if we prolonged the cooling period be-
yond the current 7–10 h. As previously described, re-
peated 5’-AMP administration was not suitable to
prolong the hypometabolism state, as it enhanced the
mortality rate [20]. Here we used a Ta of 14.5 °C in-
stead of 15 °C to prolong the hypometabolic state. Upto 17 h of cooling was achieved with this approach in
40 % of the mice. The remainder of the mice either
aroused before 12 h or failed to survive the procedure.
The data presented are from animals that had sus-
tained a single cooling period of between 12 and 17 h
and were sacrificed 24 h post-treatment for tissue col-
lection. Western analysis of the duodenal epithelial
tissues from four mice revealed that the relative ratio
of ΔF508-CFTR in band C to internal control was in-
creased compared to multiple cooling treatments of
7–10 h, while the relative ratio of ΔF508-CFTR in
band B to internal control was decreased (Fig. 2a, b).
Together, these data suggest that cooling stabilized the
ΔF508-CFTR and a longer cooling period enhanced
the formation of the complex glycosylated form of
ΔF508-CFTR in band C in vivo.
Fig. 2 5’-AMP-induced whole body cooling treatment increases stability and glycosylation of ΔF508-CFTR in intestinal epithelium - Western
analysis of intestinal duodenal epithelium. a CF mice given four treatment cycles every 72 h, with each cooling cycle lasting 7–10 h; b CF mice
that had undergone one cooling treatment lasting 12–17 h. All mice were sacrificed 24 h after the last treatment. Each gel lane represents a tissue
sample from an individual mouse. The left and right photograph reflects short and longer film exposures of the respective blot. Intestinal epithelia
from three wild type and three untreated CF mice were used as positive and negative controls for both Western analyses. A nonspecific 72 kDa
band that immune reacted with the antibody preparation was used as an internal control (IC) for loading samples
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crypts
Next we examined whether there are indicators that the
enhanced levels of ΔF508-CFTR are functionally benefi-
cial to CF mice. Mucin, the major protein component of
mucus, is largely released by goblet cells in the intestine
and thickened mucin in the lumen is a hallmark of CF
mice. Here we subjected CF mice to three cycles of
whole body cooling for 7–10 h every 72 h. Immuno-
staining of CFTR with the anti-CFTR antibody and co-
staining of mucin with fluorescence labeled wheat germ
agglutinin (WGA) were carried out using isolated intes-
tinal crypts from wild type and treated and untreated CF
mice. WGA, which binds to sialic acid and N-acetyl-D-
glucosamine on the mucin protein, was used to detect
the presence of mucin. DAPI counterstaining was also
carried out to detect nuclei. The WGA staining in wild
type was largely located within the goblet cells indicating
pre-secreted mucin and mucin staining were not apparent
in the lumen of intestinal crypts. By contrast, we observed
prominent WGA staining in the lumen, particularly at the
goblet cell outlet of untreated CF intestinal crypts, in
addition to staining in goblet cells (Fig. 3a), WGA staining
of treated CF samples showed that the majority of mucin
remained within the goblet cells similar to that observed
in wild type, while the number of strong mucin stainingcells in the lumen was highly reduced compared with un-
treated CF mice. Further, many WGA positive goblet cells
were also positively stained by anti-CFTR antibodies in
the intestinal tissues from treated but not untreated CF
mice (Fig. 3a, b). At a higher resolution, WGA mucin
staining appeared as a weak signal in wild type lumen and
much less concentrated near the goblet cell outlet of
treated CF mice comparing to untreated CF mice (Fig. 3b).
Using PAS staining, accumulation of mucus released from
goblet cells in the crypt lumen and along the villous sur-
faces was very prominent in CF but absent in wild type
animals (Fig. 3c). The accumulation of mucus in the intes-
tinal crypt lumen of CF mice was visibly reduced, accom-
panied by a visibly reduced lumen mucus density, after
repeated whole body cooling treatment. These observa-
tions suggest that after whole body cooling treatment, in-
creased ΔF508-CFTR protein stability correlates with
reduced accumulation of mucin in the intestinal lumen of
CF mice.
Increased β-adrenergic-dependent salivary secretion in
treated CF mice
Human sweat glands normally respond to both β-
adrenergic and cholinergic stimulation [33], but in CF
patients these glands fail to respond to stimulation with
isoprenaline, a β-adrenergic agonist [34]. Mice do not
Fig. 3 Reduced mucin levels in CF mouse duodenum crypts after whole body treatments. CFTR was immunostained with anti-CFTR antibodies
(red) and mucin was stained with fluorescence labeled wheat-germ agglutinin (WGA, green). a Co-staining of CFTR and mucin by anti-CFTR
antibodies and WGA. CF mice were either untreated or treated with three cycles of 7–10 h whole body cooling. b Immunostained images at
100x magnification. The arrows indicate the goblet cells. c PAS-Alcian-blue staining of mouse duodenum crypts from WT, CF and treated CF mice
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ever the salivary gland in mouse responds in the same
way as human sweat glands to β-adrenergic and cholin-
ergic stimulation. The restoration of this β-adrenergic-
dependent activity has been previously used as a func-
tional assay to evaluate the effectiveness of potential
drug therapy in restoration of CFTR function in vivo
[29]. We compared average salivary flow rates in re-
sponse to the β-adrenergic agonist isoprenaline in wild
type controls and in AIHM whole body treated and un-
treated CF mice. After blocking cholinergic dependent
secretion with atropine, isoprenaline induced an increased
salivary secretion with an average flow rate of 51.04 ±
3.16 μg min−1 g−1 in wild type mice. Consistent with pre-
vious observations, untreated CF mice (n = 30) showed a
very weak salivary secretion response to isoprenaline
stimulation, with an average flow rate of 2.56 ±
0.15 μg min−1 g−1. The isoprenaline-dependent salivary se-
cretion improved significantly in treated CF mice (n = 31),
with an average rate of 6.32 ± 0.40 μg min−1 g−1 1 day after
two cycles of whole body cooling treatments. Unlike un-
treated CF mice, where the salivary flow rate measure-
ments formed a tight cluster around 2.56 μg min−1 g−1,
the flow rate pattern distribution from individual treated
CF mice ranged up to more than 10 μg min−1 g−1. Five
days post cooling treatment, salivary secretion dropped to
5.58 ± 0.33 μg min−1 g−1 but remained higher than that of
untreated CF mice (Fig. 4a).
Next we investigated whether a single treatment of
prolonged cooling (12–17 h) would result in greater im-
provement than the multiple cooling regimes. Surpris-
ingly, salivary secretion didn’t noticeably improve in CF
mice one day post prolonged cooling treatment. How-
ever, salivary secretion significantly improved 5 days postFig. 4 β-adrenergic dependent salivary secretion is enhanced after whole b
secretion following isoprenaline injection: a Wild type, untreated and treated
b Untreated CF versus CF mice treated with a 12–17 h cooling regime at 24 h
individual mouse. * indicates statistical analysis SEM (P < 0.05)prolonged cooling treatment, with an average rate of
7.38 ± 1.03 μg min−1 g−1 (Fig. 4b). We reason that the
apparent absence of improvement at day one after pro-
longed cooling treatment could have been due to the
lack of fluid intake in treated mice following the pro-
longed stupor state. Together, these findings suggest im-
proved function of the stabilized ΔF508-CFTR after
whole body cooling treatment in vivo.
5’-AMP induced whole body cooling treatments improve
CF mouse survival
Finally, we examined whether CF mice that were given
multiple treatments with the AIHM whole body cooling
regime had reduced mortality. We reasoned that im-
proved mutant protein processing and trafficking and at
least partially restored CFTR function in vivo, could re-
sult in an improvement in the survival rate of the CF
mice. Previous studies have shown that ΔF508-CFTR
mice have a very high mortality rate up to 6 weeks of
age, with less than 40 % survival compared with over
95 % for wild type littermates [24]. The mortality rate of
CF mice older than six weeks of age dropped signifi-
cantly. To generate a large number of CF animals for
this study, we bred a homozygote CF male with hetero-
zygote CF female animals. Mice that are homozygous for
ΔF508-CFTR are significantly smaller than their hetero-
zygous siblings, a characteristic apparent by one week of
age. Genotyping a cohort of smaller versus normal size
sibling revealed a tight correlation between small pup
sizes and homozygotes for ΔF508-CFTR. Therefore, we
used size differential at age seven days as an initial
screen to identify mice homozygous for ΔF508-CFTR.
To investigate whether whole body cooling improves
survival of CF mice, starting at age seven days, CF miceody cooling treatment. The level of β-adrenergic dependent salivary
CF mice (two cycles of treatment) at 24 h and 5 days post-treatment.
and day five post-treatment. Each circle in each group represents an
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two weeks. To ascertain possible small improvements, a
large cohort of treated mice versus untreated controls
was examined. At the completion of the studies, gen-
omic DNA samples were collected from all the mice and
genotyped for homozygosity of the ΔF508 mutation. As
shown in Fig. 5, the overall mortality of CF mice was sig-
nificantly decreased in the treated group compared to
the untreated group. By the age of five weeks, the co-
horts that underwent whole body cooling treatment dis-
played an improvement in survival rate to 54 % (n =
198), compared with 39 % (n = 278) in untreated CF
mice. Noticeably, the biggest improvement in survival
was between weeks one and two of age following the on-
set of treatment. The differential mortality rate between
treated and untreated CF mice remained apparent at the
end of the experiment at six weeks of age. Together,
these findings showed that whole body cooling has a
quantifiable beneficial impact on the overall survival of
CF mice.
Discussion
Until recently, mammals in deep hypometabolism with
severe Tb reduction and stupor were only observed in
nature during hibernation and torpor [35]. Lowering
body temperature in mammals artificially has not only
been considered difficult but also dangerous, as it can
induce cardiac arrest. Our studies were the first to dem-
onstrate that the metabolite 5’-AMP can induce mice toFig. 5 Logrank analyses of survival rates. The graph represents the
Logrank analyses of survival rates of groups of treated and untreated
CF mice and heterozygote (Het) littermates; The Logrank tests (low
panels) show the statistical differences among survival curves. It shows
that the cooling treatment used in this study didn’t impact the survival
of the heterozygote CF mice, while improved the survival of CF mice
significantly. Thus, the treatment does not appear to impact the
animals negativelyundergo transient hypometabolism with a Tb as low as
26 °C when maintained at room temperature [21]. Since
then, our studies have shown that mice given 5’-AMP
can have their Tb safely reduced to 16–17 °C when kept
at a Ta of 15 °C and remain in this deep hypometabolic
state for 7–10 h [20, 22, 23, 36]. AIHM is now recog-
nized as an inducible form of torpor by investigators
who have studied natural torpor [37]. Recently, a num-
ber of independent studies have used AIHM to reduce
body temperature in order to investigate animal models
of clinical disorders thought to benefit by severe Tb re-
duction [38–40]. These studies demonstrate that AIHM
whole body cooling is safe when used under the appro-
priate conditions and could provide a beneficial treat-
ment for these disorders.
Here, we investigated whether whole body cooling
could rescue misfolded proteins in vivo. One of the best
characterized temperature-sensitive misfolded proteins is
ΔF508-CFTR, the most common mutation responsible
for CF in humans. Animal models of cystic fibrosis have
provided a powerful tool for studies of the mechanisms
and complexities of the human CF disease. Understand-
ably, the murine ΔF508-CFTR model has inherent limi-
tations due to anatomic and immunologic differences
between mice and humans. The ΔF508-CFTR CF mice
do not develop the lung inflammatory disorders caused
by chronic bacterial infections observed in human CF
patients [24, 41]. One of the difficulties in dealing with
this CF mouse model is the narrow window, the first
month post-natal, within which the CF pathology has
the most severe impact on the animals. Whole body
cooling of mice seven days post-natal had not been tried
before. Our studies show that the AIHM mediated cool-
ing treatment appeared well tolerated by mice even at
this age. A hallmark of ΔF508-CFTR CF mouse models
is the severe intestinal pathology, including goblet cell
hyperplasia, mucin accumulation in the crypts of Lieber-
kuhn, crypt dilation and intestinal obstruction [42].
These patho-physiological features mirror the meconium
ileus observed in human infants with CF [26]. Thus, we
chose to examine intestinal duodenum tissue to evaluate
the effect on ΔF508-CFTR stabilization by AIHM whole
body cooling in vivo. After whole body cooling treat-
ment, there was an increase in ΔF508-CFTR stability in
duodenum goblet cells. We reasoned that this increase
could be due to stabilization of misfolded mutant
ΔF508-CFTR proteins, similar to that observed after low
temperature treatment of ΔF508-CFTR expressing cul-
tured cells [16, 17]. The improvement in retention of the
mutant CFTR proteins was further verified by Western
analysis. However, Western analysis revealed that whole
body cooling treatment fell short in rescuing ΔF508-
CFTR fully. Although the protein levels were highly
elevated after the cooling treatments, the majority of
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lated) or band B (partially glycosylated), with only trace
levels of the fully glycosylated form present in band C.
Multiple short cooling treatments only enhanced bands
A and B suggesting that the processing of misfolded pro-
tein to band C may be a continuous event. Consistent
with this reasoning, application of a longer period of
cooling enhanced the fraction of fully rescued ΔF508-
CFTR in band C. Our findings are consistent with those
from cell culture studies, which showed that a cooling
period of at least 16 h is necessary for full glycosylation
of ΔF508-CFTR [17]. Although the current observed ef-
fect was limited by our present cooling technology, our
findings support the possibility that full glycosylation of
ΔF508-CFTR levels will be enhanced by longer cooling
periods in vivo.
Previous studies with cultured cells have reported that
CFTR protein in band B has a similar electrophysio-
logical function to that of band C [32]. The most effect-
ive way to gauge ΔF508-CFTR rescue at the organismal
level is to measure the correction or attenuation of
ΔF508-CFTR associated pathological phenotypes in re-
sponse to treatment. First, we examined whether the
whole body cooling treatment significantly reduced
mucin accumulation in the crypts of Lieberkuhn, a key
hallmark phenotype in CF mouse intestine. After PAS
staining, the reduction in mucin accumulation was vis-
ibly apparent in treated compared to untreated CF mice.
WGA staining confirmed the prominent mucin accumu-
lation around the goblet cells in untreated CF intestinal
crypt lumen and its significant reduction in treated CF
mice. In contrast, wild type intestinal crypts displayed
pre-secreted mucin within the goblet cells and no sig-
nificant staining of accumulated mucins in the lumen
was apparent.
The mucin accumulation observations are descriptive
assessments and not quantitative measurements of func-
tion. Therefore, we measured β-adrenergic dependent
salivary secretion in CF mice to provide quantitative evi-
dence of functional rescue in vivo. This analysis of saliv-
ary gland function also extended our study to another
organ severely affected by ΔF508-CFTR in mice. Con-
sistent with previous findings, β-adrenergic dependent
salivary secretions in CF animals were severely damp-
ened compared with wild type mice [29, 43]. However,
after whole body cooling, a moderate but significant im-
provement in β-adrenergic dependent salivary secretion
was apparent in treated compared with untreated CF
mice. While the average β-adrenergic dependent salivary
secretion in treated CF mice was far from the levels ob-
served in wild type animals, the upper secretion levels
observed in some treated CF mice approached 15–20 %
of the average secretion value observed in wild type
mice. Significantly, none of the untreated CF mice in thelarge cohorts displayed β-adrenergic dependent salivary
secretion of similar magnitude. We reason that the vari-
able individual responses could result from the uneven-
ness in the length of cooling for each mouse. The
variability in the length of AIHM results from the vari-
ability in the onset of arousal from a torpor-like state by
individual animals. At present, our ability to control the
onset of arousal in mice under AIHM remains limited.
In the study using prolonged cooling, there was no ap-
parent early improvement in β-adrenergic dependent
salivary secretion at 24 h post-treatment. This is likely
due to the fact that these mice may not have fully recov-
ered from 12 to 17 h in a state of deep stupor. When
fully recovered, measurements at five days post-treatment
revealed that these cohorts of treated mice on average
showed moderately better β-adrenergic dependent salivary
secretion than those that had undergone multiple regimes
of shorter whole body cooling treatments.
Finally, we examined the apparent efficacy of cooling
based on post weaning survival of the CF mice. Previous
studies have shown that mortality of this genetically
modified line of CF pups is very high especially during
the period prior to weaning. We observed a 15 % im-
provement in survival in treated versus untreated CF
pups. This differential impact on survival was especially
evident in the first week of treatment. After treatment
stopped, the differential in mortality between treated and
untreated CF mice narrowed slightly but was mostly
maintained.
Many other human diseases have been associated with
temperature-sensitive protein misfolding defects. Low
temperature treatments had been shown to be effective
in correcting such defects in cell culture. Our goal in
this study was to use the ΔF508-CFTR mouse model to
investigate whether reduction in body temperature of
the animal can recapitulate the cell culture observations
by rescuing temperature-sensitive misfolded proteins
thus enhancing their stability and function. Interestingly,
a recent study demonstrated that AMP-induced whole
body cooling in both prion infected and Alzheimer-type
mouse models could activate a cold stress response that
promotes synapse regeneration, suggesting a novel thera-
peutic approach for neurodegenerative disorders [44].
Conclusions
Our investigation demonstrates that increased stabilization
of ΔF508-CFTR in vivo can be achieved by whole body
cooling. The increased levels of ΔF508-CFTR confer im-
provement in CFTR functions, alleviate CF pathological
phenotypes and decrease mortality in CF mice. These find-
ings open up the possibility that further advances in whole
body cooling techniques may offer treatment of different
disorders arising from temperature-sensitive misfolding
defects.
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